AFP and hepatocellular carcinoma: In the second-line therapy setting, the REACH-2 trial validated ramucirumab (VEGF receptor-2 inhibitor) as an effective therapy for patients with advanced HCC and elevated AFP ≥ 400 ng/mL, with improved median overall survival of 8.5 months versus 7.3 months with placebo [119].